Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 3

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 3
---
 following the consummation of this offering, the opportunity, in lieu of purchasing shares of common stock, to purchase pre-funded warrants to purchase shares of common stock. Each pre-funded warrant will be immediately exercisable for one share at any time at the option of the holder until such pre-funded warrant is exercised in full, provided that the holder will be prohibited from exercising pre-funded warrants for shares of common stock if, as a result of such exercise, the holder, together with its affiliates and certain related parties, would own more than 4.99% (or, at the election of the purchaser, 9.99%) of the total number of shares of common stock then issued and outstanding. The assumed combined purchase price of each pre-funded warrant and common warrants is $6.39 (which is equal to the assumed combined public offering price per share and common warrants to be sold in this offering minus $0.01, the exercise price per share of each pre-funded warrant). For each pre-funded warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis. The pre-funded warrants will be sold together with common warrants in a fixed combination, with each pre-funded warrant to purchase one share accompanied by a Series A common warrant and a Series B common warrant, each warrant to purchase one share of common stock.

Each common warrant will have
an exercise price of $ per share (which will be no less than 100% of the assumed combined public offering price per share to be sold
in this offering), will be exercisable immediately on the effective date of stockholder approval of the issuance of the shares upon exercise
of the common warrants (the “Warrant Stockholder Approval Date” and such approval, the “Warrant Stockholder Approval”);
provided, however, that, if and only if the Pricing Conditions (as defined below) are met, the common warrants will be exercisable upon
issuance. As used herein “Pricing Conditions” means that the combined public offering price per share and accompanying common
warrant is such that the Warrant Stockholder Approval is not required under the rules of the Nasdaq Stock Market LLC because either (i)
the offering is an at-the-market offering under the rules of the Nasdaq Stock Market LLC and such price equals or exceeds the sum of
(a) the applicable “Minimum Price” per share under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common stock underlying
the common